206-196-6 | Sigma-Aldrich

Quality Control Range: High Sensitivity Human Cytokine Kit

/mL Control 2 SEN210 202 – 419 pg/mL IL-13 Control 1 SEN110 25 – 51 pg/mL Control 2 SEN210 206 - 428 pg/mL IFN-γ Control 1 SEN110 24 – 50 pg/mL Control 2

Quality Control Ranges: MILLIPLEX® MAP Mouse Cytokine/Chemokine Panel

Level Expected Range Units Cytokine QC Level Expected Range Units Eotaxin Control 1 94 - 196 pg/mL IL-6 Control 1 97 - 201 pg/mL LIX Control 1 109 - 226 pg/mL Control

Quality Control Range Sheet- EQC-106 and EQC-206

114 – 236 pg/mL IL-6 Control 1 86 – 179 pg/mL RANTES Control 1 32 – 66 pg/mL Control 2 432 – 897 pg/mL Control 2 155

Quality Control Ranges: MILLIPLEX® MAP Human Cytokine/ Chemokine Magnetic Bead Panel

Control 2 536 - 1113 pg/mL Control 2 561 - 1165 pg/mL Eotaxin Control 1 99 - 206 pg/mL IL-13 Control 1 105 -

XP725 Antibody Number-Lot Number 071M4826

248 269 270 271 272 3.3 201 202 203 204 225 226 227 228 249 250 251 252 273 274 275 276 3.4 205 206 207 208 229 230 231 232 253 254 255 256 277 278 279 280 3.5 209 210 211

Data Sheet - CLLS1133

increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res., 63, 196-206 (2003). 14. Sun, M. et al., Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast

Data Sheet - CLLS1063

increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res., 63, 196-206 (2003). 14. Sun, M. et al., Phosphatidylinositol-3-OH kinase (PI3K)/AKT2, activated in breast

Product Information Sheet - PKH26PCL

G.J. et al., J Exp Med, 196: 1515- 1521 (2002). 4. Maus, U. et al., Am J Resp Crit Care Med, 166, 268-273 (2002). 5. Satoh T et al, Cancer Res, 63: 7853-7860 (2003). 6. Jennings, J.H. et al.

Product Information - CSAA1

Clone:PKB-175 P2482 Signal Transduction M y y y 205 PKB/AKT P1601 Signal Transduction P y y y 206 PKB phosphoserine 473 (pS 473) P4112 Signal Transduction P n/d y y 207 PKB phosphothreonine 308

PKH Dye Reference Guide

29, 87, 126, 130, 148 Adhesion 69, 46, 196 Blood flow assessment 68 Cytotoxicity, immunotherapy 32, 127, 139, 157 Immunity/antigen presentation 6, 14, 15, 31, 81, 115

Celltransmissions Newsletter

et al., Curr. Opin. Cell Biol., 14, 160-166 (2002). 21. Xie, F. and Conti, M., Dev. Biol., 265, 196-206 (2004). 22. Zippin, J.H., et al., FASEB J., 17, 82-84 (2003). 23. Smith, C.J., et al., J. Biol. Chem

Cytoskeletal Signaling Antibodies, Reagents and Kits

Conjugate Anti-phospho-MBP, HRP conj. ELISA KA WB 50 µL 16-198 Anti-phospho-MBP, HRP conj. 50 µL 16-206 Protein MBP (myelin basic protein), bovine, purified KA 10 mg 13-104 MBP, Dephosphorylated

MAPK: Antibodies, Proteins, Kits, siRNA and Reagents

Conjugate Anti-phospho-MBP, HRP conj. ELISA KA WB 50 µL 16-198 Anti-phospho-MBP, HRP conj. 50 µL 16-206 Protein MBP (myelin basic protein), bovine, Pured KA 10 mg 13-104 MBP, Dephosphorylated KA

XP725 Antibody List Lot 129K4831

3851 KRT4 M NP_002263.2 y n/d n/d 205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3 y n/d n/d 206 Cytokeratin 8.12 C7034 3860 KRT13 M NP_002265.2 ,NP_705694.2 y n/d n/d 208 Cytokeratin peptide 13 C0791

XP725 Antibody List Lot 129K4830

3851 KRT4 M NP_002263.2 y n/d n/d 205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3 y n/d n/d 206 Cytokeratin 8.12 C7034 3860 KRT13 M NP_002265.2 ,NP_705694.2 y n/d n/d 208 Cytokeratin peptide 13 C0791

XP725 Antibody List Lot 089K4791

3851 KRT4 M NP_002263.2 y n/d n/d 205 Cytokeratin peptide 7 C6417 3855 KRT7 M NP_005547.3 y n/d n/d 206 Cytokeratin 8.12 C7034 3860 KRT13 M NP_002265.2 ,NP_705694.2 y n/d n/d 208 Cytokeratin peptide 13 C0791

User Guide Equinox SOP Software 2.1 for Windows XP

Contenido — i 193 193 193 194 194 195 198 199 199 199 200 202 202 202 203 203 203 204 204 205 205 206 206 207 207 208 208 209 209 210 210 210 211 211 213 213 213 214 214 215 215 216 216 Contenido

3D BIOPRINTING: Printing a Brighter Future

, micro pore-forming hydrogel biomaterials have been developed that can be applied to bioprinting.206–208 For example, a micro pore-forming bioink based on the aqueous two-phase emulsion (ATPE) improved

3D BIOPRINTING: Printing a Brighter Future

, micro pore-forming hydrogel biomaterials have been developed that can be applied to bioprinting.206–208 For example, a micro pore-forming bioink based on the aqueous two-phase emulsion (ATPE) improved

Material Matters Volume 15 number 2 Batteries & Solar Cells

cell-efficiency.html. (6) Saliba, M.; Matsui, T.; Domanski, K.; Seo, J.-Y.; Ummadisingu, A.; Zakeeruddin, S. M.; Correa-Baena, J.-P.;. Tress, W. R; Abate, A.; Hagfeldt, A.; Grätzel, M. Science, 2016, 354, 206–209.

List of Antibodies

C5176 M y n/d n/d 204 Cytokeratin CK5 C7785 M y n/d n/d 205 Cytokeratin peptide 7 C6417 M y n/d n/d 206 Cytokeratin 8.12 C7034 M y n/d n/d 207 Cytokeratin 8.13 C6909 M y n/d n/d 208 Cytokeratin peptide 13

Halal Certificate

Product Code Halal-ID Product Certificate # 205. 2-UNDECANONE NATURAL W309311 D12699 HC-23SI5M30 206. 2-Undecen-1-Ol W406801 A99884 HC-23SIM320 207. 3-(METHYLTHIO)-1-HEXANOL W343803 C44272 HC-23SIAT77

Halal Certificate

Product Code Halal-ID Product Certificate # 205. 2-UNDECANONE NATURAL W309311 D12699 HC-22SIU951 206. 2-Undecen-1-Ol W406801 A99884 HC-22SI2S41 207. 3-(METHYLTHIO)-1-HEXANOL W343803 C44272 HC-22SIHP98

XP725 Antibody List 013M4793

3875 KRT18 NP_954657.1 M y n/d n/d 205 Cytokeratin peptide 7 C6417 3855 KRT7 NP_005547.3 M y n/d n/d 206 Cytokeratin 8.12 C7034 3866, 3860, 3868 KRT15,KRT16,KRT13 NP_002266.2,NP_705694.2,NP_005548.2 M y n

XP725 Antibody List

3875 KRT18 NP_954657.1 M y n/d n/d 205 Cytokeratin peptide 7 C6417 3855 KRT7 NP_005547.3 M y n/d n/d 206 Cytokeratin 8.12 C7034 3866, 3860, 3868 KRT15,KRT16,KRT13 NP_002266.2,NP_705694.2,NP_005548.2 M y n